New screens and targets in antibacterial drug discovery

Current Opinion in Microbiology

Volumn 12, Issue 5, 2009, Pages 497-504

  Falconer, Shannon B ^a,b   Brown, Eric D ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACTINONIN; ANTIINFECTIVE AGENT; BAMBERMYCIN; CHIR 090; FATTY ACID; N (5 FLUORO 1 OXIDO 2 PYRIDINYL) 1 [2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANOYL]PROLINAMIDE; N [1 TERT BUTYL 2 OXO 2 [4 (2 THIAZOLYLMETHYL) 1 PIPERAZINYL]ETHYL] 3 CYCLOPENTYL 2 (N FORMYL N HYDROXYAMINOMETHYL)PROPIONAMIDE; PEPTIDE DEFORMYLASE; PEPTIDE DEFORMYLASE INHIBITOR; PLATENCIN; PLATENSIMYCIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; BACTERIAL CELL; BACTERIOPHAGE; CELL SURFACE; CHEMICAL ANALYSIS; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; ESSENTIAL GENE; HUMAN; METHODOLOGY; NONHUMAN; PHENOTYPE; REVIEW; VIRULENCE;

AMIDOHYDROLASES; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIOPHAGES; DRUG DISCOVERY; HUMANS; MODELS, BIOLOGICAL; TEICHOIC ACIDS;

BACTERIA (MICROORGANISMS);

EID: 70349971143     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mib.2009.07.001     Document Type: Review

References (53)

1. Clatworthy A., Pierson E., and Hung D. Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol 3 (2007) 541-548
2. Arnoldo A., Curak J., Kittanakom S., Chevelev I., Lee V., Sahebol-Amri M., Koscik B., Ljuma L., Roy P., Bedalov A., et al. Identification of small molecule inhibitors of Pseudomonas aeruginosa exoenzyme S using a yeast phenotypic screen. Public Library Sci Genet 4 (2008) e1000005. This publication describes a novel screening approach that is capable of identifying leads with new mechanisms of action, such as targeting virulence.
3. Moy T., Ball A., Anklesaria Z., Casadei G., Lewis K., and Ausubel F. Identification of novel antimicrobials using a live-animal infection model. Proc Natl Acad Sci U S A 103 (2006) 10414-10419
4. Vollmer W., Blanot D., and de Pedro M. Peptidoglycan structure and architecture. FEMS Microbiol Rev 32 (2008) 149-167
5. Barb A., Jiang L., Raetz C., and Zhou P. Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: time-dependent inhibition and specificity in ligand binding. Proc Natl Acad Sci U S A 104 (2007) 18433-18438. This is the first report of a structure of the LpxC-CHIR-090 complex.
6. Barb A., McClerren A., Snehelatha K., Reynolds C., Zhou P., and Raetz C. Inhibition of lipid A biosynthesis as the primary mechanism of CHIR-090 antibiotic activity in Escherichia coli. Biochemistry 46 (2007) 3793-3802
7. Mdluli K., Witte P., Kline T., Barb A., Erwin A., Mansfield B., McClerren A., Pirrung M., Tumey N., Warrener P., et al. Molecular variation of LpxC as an antibacterial drug target in Pseudomonas aeruginosa. Antimicrob Agents Chemother 50 (2006) 2178-2184
8. McClerren A., Endsley S., Bowman J., Andersen N., Guan Z., Rudolph J., and Raetz C. A slow, tight-binding inhibitor of the zinc-dependent deacetylase LpxC of lipid A biosynthesis with antibiotic activity comparable to ciprofloxacin. Biochemistry 44 (2005) 16574-16583
9. Lovering A., de Castro L., Lim D., and Strynadka C. Structural insight into the transglycosylation step of bacterial cell-wall biosynthesis. Science 315 (2007) 1402-1405. This is the first report of a peptidoglycan glycosyltransferase structure that is complexed with the antibiotic, moenomycin. The unliganded structure is also presented here.
10. Yuan Y., Barrett D., Zhang Y., Kahne D., Sliz P., and Walker S. Crystal structure of a peptidoglycan glycosyltransferase suggests a model for processive glycan chain synthesis. Proc Natl Acad Sci U S A 104 (2007) 5348-5353
11. Yuan Y., Fuse S., Ostash B., Sliz P., Kahne D., and Walker S. Structural analysis of the contacts anchoring moenomycin to peptidoglycan glycosyltransferases and implications for antibiotic design. ACS Chem Biol 3 (2008) 429-436
12. Lovering A., de Castro L., and Strynadka N. Identification of dynamic structural motifs involved in peptidoglycan glycosyltransfer. J Mol Biol 383 (2008) 167-177
13. Sung M., Lai Y., Huang C., Chou L., Shih H., Cheng W., Wong C., and Ma C. Crystal structure of the membrane-bound bifunctional transglycosylase PBP1b from Escherichia coli. Proc Natl Acad Sci U S A 106 (2009) 8824-8829
14. Murakami R., Muramatsu Y., Minami E., Masuda K., Sakaida Y., Endo S., Suzuki T., Ishida O., Takatsu T., Miyakoshi S., et al. A novel assay of bacterial peptidoglycan synthesis for natural product screening. J Antibiot 62 (2009) 153-158
15. Blake K., O'Neill A., Mengin-Lecreulx D., Henderson P., Bostock J., Dunsmore C., Simmons K., Fishwick C., Leeds J., and Chopra I. The nature of Staphylococcus aureus MurA and MurZ and approaches for detection of peptidoglycan biosynthesis inhibitors. Mol Microbiol 72 (2009) 335-343
16. Turk S., Kovac A., Boniface A., Bostock J., Chopra I., Blanot D., and Gobec S. Discovery of new inhibitors of the bacterial peptidoglycan biosynthesis enzymes MurD and MurF by structure-based virtual screening. Bioorg Med Chem 17 (2009) 1884-1889
17. Kovac A., Konc J., Vehar B., Bostock J., Chopra I., Janezic D., and Gobec S. Discovery of new inhibitors of d-alanine:d-alanine ligase by structure-based virtual screening. J Med Chem 11 (2008) 7442-7448
18. Bhavsar A., and Brown E. Cell wall assembly in Bacillus subtilis: how spirals and spaces challenge paradigms. Mol Microbiol 60 (2006) 1077-1090
19. Oku Y., Kurokawa K., Matsuo M., Yamada S., Lee B., and Sekimizu K. Pleiotropic roles of polyglycerolphosphate synthase of lipoteichoic acid in growth of Staphylococcus aureus cells. J Bacteriol 191 (2009) 141-151
20. Schirner K., Marles-Wright J., Lewis R., and Errington J. Distinct and essential morphogenic functions for wall- and lipo-teichoic acids in Bacillus subtilis. Eur Mol Biol Organ 28 (2009) 830-842
21. Zhang Y., Ginsberg C., Yuan Y., and Walker S. Acceptor substrate selectivity and kinetic mechanism of Bacillus subtilis TagA. Biochemistry 45 (2006) 10895-10904
22. Schertzer J., and Brown E. Purified, recombinant TagF protein from Bacillus subtilis 168 catalyzes the polymerization of glycerol phosphate onto a membrane acceptor in vitro. J Biol Chem 278 (2003) 18002-18007
23. Lazarevic V., and Karamata D. The tagGH operon of Bacillus subtilis 168 encodes a two-component ABC transporter involved in the metabolism of two wall teichoic acids. Mol Microbiol 16 (1995) 345-355
24. Formstone A., Carballido-Lopez R., Noirot P., Errington J., and Scheffers D. Localization and interactions of teichoic acid synthetic enzymes in Bacillus subtilis. J Bacteriol 190 (2008) 1812-1821
25. D'Elia M., Henderson J., Beveridge T., Heinrichs D., and Brown E. The N-acetylmannosamine transferase catalyzes the first committed step in teichoic acid assembly in Bacillus subtilis and Staphylococcus aureus. J Bacteriol 191 (2009) 4030-4034
26. Brown S., Zhang Y., and Walker S. A revised pathway proposed for Staphylococcus aureus wall teichoic acid biosynthesis based on in vitro reconstitution of the intracellular steps. Chem Biol 15 (2008) 12-21
27. Meredith T., Swoboda J., and Walker S. Late-stage polyribitol phosphate wall teichoic acid biosynthesis in Staphylococcus aureus. J Bacteriol 190 (2008) 3046-3056
28. Pereira M., D'Elia M., Troczynska J., and Brown E. Duplication of teichoic acid biosynthetic genes in Staphylococcus aureus leads to functionally redundant poly(ribitol phosphate) polymerases. J Bacteriol 190 (2008) 5642-5649
29. Bhavsar A., Erdman L., Schertzer J., and Brown E. Teichoic acid is an essential polymer in Bacillus subtilis that is functionally distinct from teichuronic acid. J Bacteriol 186 (2004) 7865-7873
30. Briehl M., Pooley H., and Karamata D. Mutants of Bacillus subtilis 168 thermosensitive for growth and wall teichoic acid synthesis. J Gen Microbiol 135 (1989) 1325-1334
31. Brandt C., and Karamata D. Thermosensitive Bacillus subtilis mutants which lyse at the non-permissive temperature. J Gen Microbiol 133 (1987) 1159-1170
32. D'Elia M., Millar K., Beveridge T., and Brown E. Wall teichoic acid polymers are dispensable for cell viability in Bacillus subtilis. J Bacteriol 188 (2006) 8313-8316
33. Pooley H., Abellan F., and Karamata D. A conditional-lethal mutant of Bacillus subtilis 168 with a thermosensitive glycerol-3-phosphate cytidylyltransferase, an enzyme specific for the synthesis of the major teichoic acid. J Gen Microbiol 137 (1991) 921-928
34. D'Elia M., Pereira M., Chung Y., Zhao W., Chau A., Kenney T., Sulavik M., Black T., and Brown E. Lesions in teichoic acid biosynthesis in Staphylococcus aureus lead to a lethal gain of function in the otherwise dispensable pathway. J Bacteriol 188 (2006) 4183-4189
35. D'Elia M., Millar K., Bhavsar A., Tomljenovic A., Hutter B., Schaab C., Moreno-Hagelsieb G., and Brown E. Probing teichoic acid genetics with bioactive molecules reveals new interactions among diverse processes in bacterial cell wall biogenesis. Chem Biol 16 (2009) 548-556. This publication provides new evidence for genetic interactions among isoprenoid, peptidoglycan, and teichoic acid biosynthesis.
36. Weidenmaier C., Peschel A., Xiong Y., Kristian S., Dietz K., Yeaman M., and Bayer A. Lack of wall teichoic acids in Staphylococcus aureus leads to reduced interactions with endothelial cells and to attenuated virulence in a rabbit model of endocarditis. J Infect Dis 191 (2005) 1771-1777
37. Weidenmaier C., Kokai-Kun J., Kristian S., Chanturiya T., Kalbacher H., Gross M., Nicholson G., Neumeister B., Mond J., and Peschel A. Role of teichoic acids in Staphylococcus aureus nasal colonization, a major risk factor in nosocomial infections. Nat Med 10 (2004) 243-245
38. Neuhaus F., and Baddiley J. A continuum of anioic charge: structures and functions of d-alanyl-teichoic acids in Gram-positive bacteria. Microb Mol Biol Rev 67 (2003) 686-723
39. Grundling A., and Schneewind O. Synthesis of glycerol phosphate lipoteichoic acid in Staphylococcus aureus. Proc Natl Acad Sci U S A 104 (2007) 8478-8483. This paper reports the identification of ltas and demonstrates that the loss of LTA is accompanied by profound defects in the growth of S. aureus.
40. Lu D., Wormann M., Zhang X., Schneewind O., Grundling A., and Freemont P. Structure-based mechanism of lipoteichoic acid synthesis by Staphylococcus aureus LtaS. Proc Natl Acad Sci U S A 106 (2009) 1584-1589. This publication presents the first crystal structure of the extracellular portion of S. aureus LtaS.
41. Pereira M., Blanchard J., Murphy C., Roderick S., and Brown E. High-throughput screening identifies novel inhibitors for the acetyltransferase activity of Escherichia coli GlmU. Antimicrob Agents Chemother 53 (2009) 2306-2311
42. Merril C., Scholl D., and Adhya S. The prospect for bacteriophage therapy in Western medicine. Nat Rev Drug Discov 2 (2003) 489-497
43. Schuch R., Nelson D., and Fischetti V. A bacteriolytic agent that detects and kills Bacillus anthracis. Science 418 (2002) 884-889
44. Loeffler J., Nelson D., and Fischetti V. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 294 (2001) 2170-2172
45. Lu T., and Collins J. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc Natl Acad Sci U S A 106 (2009) 4629-4634. This is the first work to show that bacteriophage engineered to target nonessential bacterial gene networks can serve as effective antibiotic adjuvants.
46. Bingel-Erlenmeyer R., Kohler R., Kramer G., Sandikci A., Antolic S., Maier T., Schaffitzel C., Wiedmann B., Bukau B., and Ban N. A peptide deformylase-ribosome complex reveals mechanism of nascent chain processing. Nature 452 (2008) 108-113
47. Chen D., Patel D., Hackbarth C., Wang W., Dreyer G., Young D., Margolis P., Wu C., Ni Z., J T., et al. Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry 39 (2000) 1256-1262
48. Chen D., and Yuan Z. Therapeutic potential of peptide deformylase inhibitors. Expert Opin Investig Drugs 14 (2005) 1107-1116
49. Leeds J., and Dean C. Peptide deformylase as an antibacterial target: a critical assessment. Curr Opin Pharmacol 6 (2006) 445-452
50. Wright H., and Reynolds K. Antibacterial targets in fatty acid biosynthesis. Curr Opin Microbiol 10 (2007) 447-453
51. Wang J., Soisson S., Young K., Shoop W., Kodali S., Galgoci A., Painter R., Parthasarathy G., Tang Y., Cummings R., et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 18 (2006) 358-361
52. Wang J., Kodali S., Lee S., Galgoci A., Painter R., Dorso K., Racine F., Motyl M., Hernandez L., Tinney E., et al. Discovery of platencin, a dual FabF and FabH inhibitor with in vivo antibiotic properties. Proc Natl Acad Sci U S A 104 (2007) 7612-7616
53. Brinster S., Lamberet G., Staels B., Trieu-Cuot P., Gruss A., and Poyart C. Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens. Nature 458 (2009) 83-86. The results of this study show that the enzymes of the FASII pathway are not effective antibacterial targets during in vivo studies with S. agalactiae, and thus cast controversy over the use of FASII-targeting antibacterials during the treatment of Gram-positive pathogen infection.